Stock A AGILENT TECHNOLOGIES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Agilent Technologies, Inc.

Equities

A

US00846U1016

Advanced Medical Equipment & Technology

Market Closed - Nyse
Other stock markets
 04:00:02 2024-06-05 pm EDT 		5-day change 1st Jan Change
133.6 USD +2.07% Intraday chart for Agilent Technologies, Inc. -8.19% -3.93%
Jun. 05 Agilent Technologies Insider Sold Shares Worth $254,540, According to a Recent SEC Filing MT
Jun. 05 Agilent Technologies Seeks M&A CI

Valuation

Fiscal Period: October 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 23,442 31,475 47,676 40,957 30,245 38,968 - -
Enterprise Value (EV) 1 24,467 32,393 48,830 42,673 31,390 39,945 39,966 41,539
P/E ratio 22.5 x 44.4 x 40 x 33.1 x 24.7 x 29.4 x 26.9 x 24.3 x
Yield 0.87% 0.71% 0.49% 0.61% - 0.7% 0.74% 0.82%
Capitalization / Revenue 4.54 x 5.9 x 7.54 x 5.98 x 4.43 x 6.03 x 5.67 x 5.31 x
EV / Revenue 4.74 x 6.07 x 7.73 x 6.23 x 4.59 x 6.18 x 5.82 x 5.66 x
EV / EBITDA 18.6 x 24.3 x 29.6 x 20.8 x 16.1 x 21.2 x 19.2 x 18.3 x
EV / FCF 28.3 x 40.4 x 37.6 x 41.8 x 21.3 x 30.8 x 26.1 x 24.2 x
FCF Yield 3.54% 2.48% 2.66% 2.39% 4.7% 3.25% 3.83% 4.13%
Price to Book 5.07 x 6.54 x 8.83 x 7.8 x 5.23 x 6.25 x 5.51 x 4.73 x
Nbr of stocks (in thousands) 309,468 308,310 302,723 296,041 292,587 291,761 - -
Reference price 2 75.75 102.1 157.5 138.4 103.4 133.6 133.6 133.6
Announcement Date 11/25/19 11/23/20 11/22/21 11/21/22 11/20/23 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: October 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 5,163 5,339 6,319 6,848 6,833 6,459 6,867 7,341
EBITDA 1 1,315 1,335 1,650 2,051 1,955 1,886 2,079 2,274
EBIT 1 1,202 1,211 1,523 1,857 1,875 1,710 1,885 2,059
Operating Margin 23.28% 22.68% 24.1% 27.12% 27.44% 26.48% 27.45% 28.05%
Earnings before Tax (EBT) 1 919 842 1,360 1,504 1,339 1,347 1,463 1,572
Net income 1 1,071 719 1,210 1,254 1,240 1,305 1,426 1,550
Net margin 20.74% 13.47% 19.15% 18.31% 18.15% 20.21% 20.76% 21.12%
EPS 2 3.370 2.300 3.940 4.180 4.190 4.550 4.973 5.497
Free Cash Flow 1 866 802 1,297 1,021 1,474 1,298 1,530 1,714
FCF margin 16.77% 15.02% 20.53% 14.91% 21.57% 20.1% 22.27% 23.34%
FCF Conversion (EBITDA) 65.86% 60.07% 78.61% 49.78% 75.4% 68.85% 73.57% 75.37%
FCF Conversion (Net income) 80.86% 111.54% 107.19% 81.42% 118.87% 99.47% 107.27% 110.54%
Dividend per Share 2 0.6560 0.7200 0.7760 0.8400 - 0.9370 0.9907 1.089
Announcement Date 11/25/19 11/23/20 11/22/21 11/21/22 11/20/23 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: October 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2 2025 Q3
Net sales 1 1,674 1,607 1,718 1,849 1,756 1,717 1,672 1,688 1,658 1,573 1,557 1,670 1,694 1,645 1,662
EBITDA 1 517 454 503 578 507 473 523 504 464 432 459 521.5 509.4 474 500
EBIT 1 486 422 471 538 476 440 490 469 428 395 415 472.2 456.9 428.3 441.1
Operating Margin 29.03% 26.26% 27.42% 29.1% 27.11% 25.63% 29.31% 27.78% 25.81% 25.11% 26.65% 28.27% 26.97% 26.03% 26.54%
Earnings before Tax (EBT) - - - 455 410 - - - - - - - - - -
Net income 1 283 274 329 368 352 302 111 475 348 308 346.2 389.4 396.1 373.3 378.5
Net margin 16.91% 17.05% 19.15% 19.9% 20.05% 17.59% 6.64% 28.14% 20.99% 19.58% 22.23% 23.31% 23.39% 22.69% 22.78%
EPS 2 0.9300 0.9100 1.100 1.230 1.190 1.020 0.3800 1.620 1.180 1.050 1.144 1.339 1.328 1.295 1.311
Dividend per Share 2 0.2100 0.2100 0.2100 0.2100 0.2250 0.2250 - - 0.2360 - 0.2358 0.2368 0.2380 0.2314 0.2249
Announcement Date 2/22/22 5/24/22 8/16/22 11/21/22 2/28/23 5/23/23 8/15/23 11/20/23 2/27/24 5/29/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: October 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 1,025 918 1,154 1,716 1,145 978 999 2,571
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 0.7795 x 0.6876 x 0.6994 x 0.8367 x 0.5857 x 0.5186 x 0.4805 x 1.131 x
Free Cash Flow 1 866 802 1,297 1,021 1,474 1,298 1,530 1,714
ROE (net income / shareholders' equity) 21.2% 21.3% 26% 29.3% 28.3% 24% 23.5% 24.3%
ROA (Net income/ Total Assets) 11% 10.7% 13.1% 14.7% 15.1% 12.7% 13.2% 13.2%
Assets 1 9,742 6,705 9,235 8,502 8,225 10,251 10,840 11,789
Book Value Per Share 2 14.90 15.60 17.80 17.70 19.70 21.40 24.30 28.20
Cash Flow per Share 2 3.210 2.950 4.870 4.370 5.990 5.670 6.560 7.110
Capex 1 155 119 188 291 298 386 349 333
Capex / Sales 3% 2.23% 2.98% 4.25% 4.36% 5.98% 5.08% 4.54%
Announcement Date 11/25/19 11/23/20 11/22/21 11/21/22 11/20/23 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Agilent Technologies, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
A
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
133.6 USD
Average target price
140.1 USD
Spread / Average Target
+4.91%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

1st Jan change Capi.
AGILENT TECHNOLOGIES, INC. Stock Agilent Technologies, Inc.
-3.93% 38.97B
THERMO FISHER SCIENTIFIC Stock Thermo Fisher Scientific
+8.38% 220B
DANAHER CORPORATION Stock Danaher Corporation
+15.78% 198B
BOSTON SCIENTIFIC CORPORATION Stock Boston Scientific Corporation
+31.27% 112B
SIEMENS HEALTHINEERS AG Stock Siemens Healthineers AG
+3.76% 66.17B
EDWARDS LIFESCIENCES CORPORATION Stock Edwards Lifesciences Corporation
+14.19% 52.47B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. Stock Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
+4.70% 50.77B
GE HEALTHCARE TECHNOLOGIES INC. Stock GE HealthCare Technologies Inc.
-0.47% 35.13B
RESMED, INC. Stock ResMed, Inc.
+23.96% 31.32B
PHILIPS NV Stock Philips NV
+19.09% 24.73B
Other Advanced Medical Equipment & Technology
  1. Stock Market
  2. Equities
  3. A Stock
  4. Financials Agilent Technologies, Inc.